CA2919996A1 - Methods for the treatment of solid tumors - Google Patents

Info

Publication number

CA2919996A1

CA2919996A1 CA2919996A CA2919996A CA2919996A1 CA 2919996 A1 CA2919996 A1 CA 2919996A1 CA 2919996 A CA2919996 A CA 2919996A CA 2919996 A CA2919996 A CA 2919996A CA 2919996 A1 CA2919996 A1 CA 2919996A1

Authority

CA

Canada

Prior art keywords

substituted

cancer

unsubstituted

carcinoma

combination

Prior art date

2013-08-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 216
• 238000011282 treatment Methods 0.000 title claims abstract description 85
• 238000000034 method Methods 0.000 title claims description 55
• 239000003112 inhibitor Substances 0.000 claims abstract description 151
• 239000003276 histone deacetylase inhibitor Substances 0.000 claims abstract description 123
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical group C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 247
• 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 241
• 229960001507 ibrutinib Drugs 0.000 claims description 241
• MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical group O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims description 203
• 229950008805 abexinostat Drugs 0.000 claims description 195
• 102100036409 Activated CDC42 kinase 1 Human genes 0.000 claims description 157
• 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 claims description 157
• 150000001875 compounds Chemical class 0.000 claims description 156
• 125000000217 alkyl group Chemical group 0.000 claims description 135
• 201000009030 Carcinoma Diseases 0.000 claims description 124
• 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 122
• 229940124291 BTK inhibitor Drugs 0.000 claims description 106
• 239000000203 mixture Substances 0.000 claims description 95
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 77
• 239000003814 drug Substances 0.000 claims description 77
• -1 AG-F-54930) Chemical compound 0.000 claims description 73
• 125000001072 heteroaryl group Chemical group 0.000 claims description 64
• 125000003118 aryl group Chemical group 0.000 claims description 61
• 230000002427 irreversible effect Effects 0.000 claims description 52
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 49
• 101150015280 Cel gene Proteins 0.000 claims description 48
• 206010005003 Bladder cancer Diseases 0.000 claims description 47
• 201000005202 lung cancer Diseases 0.000 claims description 47
• 208000020816 lung neoplasm Diseases 0.000 claims description 47
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 46
• 208000009956 adenocarcinoma Diseases 0.000 claims description 46
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 46
• 125000000623 heterocyclic group Chemical group 0.000 claims description 42
• 208000006990 cholangiocarcinoma Diseases 0.000 claims description 39
• 238000011260 co-administration Methods 0.000 claims description 38
• 206010004593 Bile duct cancer Diseases 0.000 claims description 37
• 206010033128 Ovarian cancer Diseases 0.000 claims description 37
• 206010039491 Sarcoma Diseases 0.000 claims description 37
• RRHONYZEMUNMJX-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3-methylbutan-2-ylamino)methyl]benzamide Chemical compound C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)C)C=C1 RRHONYZEMUNMJX-UHFFFAOYSA-N 0.000 claims description 36
• 208000026310 Breast neoplasm Diseases 0.000 claims description 35
• 206010006187 Breast cancer Diseases 0.000 claims description 34
• 206010060862 Prostate cancer Diseases 0.000 claims description 33
• 125000003342 alkenyl group Chemical group 0.000 claims description 33
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 31
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 31
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 30
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 30
• 201000002528 pancreatic cancer Diseases 0.000 claims description 30
• 206010009944 Colon cancer Diseases 0.000 claims description 28
• 208000026900 bile duct neoplasm Diseases 0.000 claims description 28
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 28
• 229910052739 hydrogen Inorganic materials 0.000 claims description 28
• 239000001257 hydrogen Substances 0.000 claims description 28
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 28
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 28
• 239000002552 dosage form Substances 0.000 claims description 27
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 26
• 125000000304 alkynyl group Chemical group 0.000 claims description 25
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 25
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 24
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 21
• 229910052799 carbon Inorganic materials 0.000 claims description 20
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
• 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 18
• 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 17
• 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 17
• 208000014081 polyp of colon Diseases 0.000 claims description 17
• JIFCFQDXHMUPGP-UHFFFAOYSA-N 4-tert-butyl-n-[2-methyl-3-[4-methyl-6-[4-(morpholine-4-carbonyl)anilino]-5-oxopyrazin-2-yl]phenyl]benzamide Chemical compound C1=CC=C(C=2N=C(NC=3C=CC(=CC=3)C(=O)N3CCOCC3)C(=O)N(C)C=2)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 JIFCFQDXHMUPGP-UHFFFAOYSA-N 0.000 claims description 16
• 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 16
• BSSBAJKNZOHHCA-UHFFFAOYSA-N 7-benzyl-1-(3-piperidin-1-ylpropyl)-2-(4-pyridin-4-ylphenyl)-5h-imidazo[4,5-g]quinoxalin-6-one Chemical compound C1CCCCN1CCCN1C=2C=C3N=C(CC=4C=CC=CC=4)C(=O)NC3=CC=2N=C1C(C=C1)=CC=C1C1=CC=NC=C1 BSSBAJKNZOHHCA-UHFFFAOYSA-N 0.000 claims description 16
• 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 16
• 201000009546 lung large cell carcinoma Diseases 0.000 claims description 16
• 208000000649 small cell carcinoma Diseases 0.000 claims description 16
• SMOPKEHQPPXRSH-UHFFFAOYSA-N 2-methyl-n-[2-[3-[[2-(prop-2-enoylamino)acetyl]amino]anilino]pyrimidin-5-yl]-5-[[3-(trifluoromethyl)benzoyl]amino]benzamide Chemical compound C1=C(C(=O)NC=2C=NC(NC=3C=C(NC(=O)CNC(=O)C=C)C=CC=3)=NC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 SMOPKEHQPPXRSH-UHFFFAOYSA-N 0.000 claims description 15
• SEJLPXCPMNSRAM-GOSISDBHSA-N 6-amino-9-[(3r)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one Chemical compound C1N(C(=O)C#CC)CC[C@H]1N1C(=O)N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C21 SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 claims description 15
• 229940126656 GS-4224 Drugs 0.000 claims description 15
• ABSXPNGWJFAPRT-UHFFFAOYSA-N benzenesulfonic acid;n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 ABSXPNGWJFAPRT-UHFFFAOYSA-N 0.000 claims description 15
• 239000002775 capsule Substances 0.000 claims description 15
• DQPJVNQWPBLBAB-UHFFFAOYSA-N n-[5-[[3-(4-acetylpiperazine-1-carbonyl)-4,5-dimethylphenyl]methylsulfanyl]-1,3-thiazol-2-yl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide Chemical compound C1=CC(CNC(C)C(C)(C)C)=CC=C1C(=O)NC(S1)=NC=C1SCC1=CC(C)=C(C)C(C(=O)N2CCN(CC2)C(C)=O)=C1 DQPJVNQWPBLBAB-UHFFFAOYSA-N 0.000 claims description 15
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 11
• 125000003545 alkoxy group Chemical group 0.000 claims description 11
• 125000002947 alkylene group Chemical group 0.000 claims description 11
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims description 10
• 206010073099 Lobular breast carcinoma in situ Diseases 0.000 claims description 10
• 125000004414 alkyl thio group Chemical group 0.000 claims description 10
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 10
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 10
• 125000001188 haloalkyl group Chemical group 0.000 claims description 10
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
• 206010004992 Bladder adenocarcinoma stage unspecified Diseases 0.000 claims description 9
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
• 201000006107 Familial adenomatous polyposis Diseases 0.000 claims description 9
• 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims description 9
• ZHXNIYGJAOPMSO-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide Chemical compound C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)(C)C)C=C1 ZHXNIYGJAOPMSO-UHFFFAOYSA-N 0.000 claims description 9
• 201000007180 bile duct carcinoma Diseases 0.000 claims description 9
• 201000006587 bladder adenocarcinoma Diseases 0.000 claims description 9
• 201000005389 breast carcinoma in situ Diseases 0.000 claims description 9
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims description 9
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 9
• 201000009777 distal biliary tract carcinoma Diseases 0.000 claims description 9
• 201000007273 ductal carcinoma in situ Diseases 0.000 claims description 9
• 229910052736 halogen Inorganic materials 0.000 claims description 9
• 150000002367 halogens Chemical class 0.000 claims description 9
• 125000005549 heteroarylene group Chemical group 0.000 claims description 9
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims description 9
• 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 9
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims description 9
• 201000011059 lobular neoplasia Diseases 0.000 claims description 9
• 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 9
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
• 201000002530 pancreatic endocrine carcinoma Diseases 0.000 claims description 9
• 229910052717 sulfur Inorganic materials 0.000 claims description 9
• 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 8
• 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 8
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
• 125000004438 haloalkoxy group Chemical group 0.000 claims description 8
• 125000004475 heteroaralkyl group Chemical group 0.000 claims description 8
• 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 8
• CDOOFZZILLRUQH-GDLZYMKVSA-N n-[3-[6-[4-[(2r)-1,4-dimethyl-3-oxopiperazin-2-yl]anilino]-4-methyl-5-oxopyrazin-2-yl]-2-methylphenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide Chemical compound CN1CCN(C)C(=O)[C@H]1C(C=C1)=CC=C1NC1=NC(C=2C(=C(NC(=O)C=3SC=4CCCCC=4C=3)C=CC=2)C)=CN(C)C1=O CDOOFZZILLRUQH-GDLZYMKVSA-N 0.000 claims description 8
• 229910052760 oxygen Inorganic materials 0.000 claims description 8
• 125000004660 phenylalkylthio group Chemical group 0.000 claims description 8
• 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 8
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 7
• 206010023774 Large cell lung cancer Diseases 0.000 claims description 7
• 238000001990 intravenous administration Methods 0.000 claims description 7
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
• 239000007909 solid dosage form Substances 0.000 claims description 6
• 230000002611 ovarian Effects 0.000 claims description 2
• 125000001475 halogen functional group Chemical group 0.000 claims 2
• DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 2
• 238000011161 development Methods 0.000 abstract description 4
• 208000037765 diseases and disorders Diseases 0.000 abstract 1
• 241000699670 Mus sp. Species 0.000 description 48
• 210000004027 cell Anatomy 0.000 description 39
• 229940079593 drug Drugs 0.000 description 29
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 28
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 28
• 125000004429 atom Chemical group 0.000 description 26
• 201000011510 cancer Diseases 0.000 description 25
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
• 206010024627 liposarcoma Diseases 0.000 description 21
• 201000008968 osteosarcoma Diseases 0.000 description 21
• 238000009472 formulation Methods 0.000 description 20
• 125000005842 heteroatom Chemical group 0.000 description 20
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
• 238000002560 therapeutic procedure Methods 0.000 description 19
• HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 18
• 241000699666 Mus <mouse, genus> Species 0.000 description 16
• 201000010099 disease Diseases 0.000 description 16
• 125000004432 carbon atom Chemical group C* 0.000 description 15
• 230000002354 daily effect Effects 0.000 description 15
• 208000005243 Chondrosarcoma Diseases 0.000 description 14
• 201000008808 Fibrosarcoma Diseases 0.000 description 14
• 206010073137 Myxoid liposarcoma Diseases 0.000 description 14
• 230000024245 cell differentiation Effects 0.000 description 14
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
• 125000004122 cyclic group Chemical group 0.000 description 14
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 14
• 230000000694 effects Effects 0.000 description 14
• 230000004044 response Effects 0.000 description 14
• 235000018417 cysteine Nutrition 0.000 description 13
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 13
• 125000005843 halogen group Chemical group 0.000 description 13
• 210000004072 lung Anatomy 0.000 description 13
• 241000699660 Mus musculus Species 0.000 description 12
• 206010041067 Small cell lung cancer Diseases 0.000 description 12
• 208000000587 small cell lung carcinoma Diseases 0.000 description 12
• 238000001356 surgical procedure Methods 0.000 description 12
• 238000011830 transgenic mouse model Methods 0.000 description 12
• 230000002411 adverse Effects 0.000 description 11
• 210000004369 blood Anatomy 0.000 description 11
• 239000008280 blood Substances 0.000 description 11
• 208000029742 colonic neoplasm Diseases 0.000 description 11
• 239000008194 pharmaceutical composition Substances 0.000 description 11
• 239000000243 solution Substances 0.000 description 11
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 10
• 208000003174 Brain Neoplasms Diseases 0.000 description 10
• 230000036210 malignancy Effects 0.000 description 10
• 210000001519 tissue Anatomy 0.000 description 10
• 206010008342 Cervix carcinoma Diseases 0.000 description 9
• 206010027476 Metastases Diseases 0.000 description 9
• 208000000453 Skin Neoplasms Diseases 0.000 description 9
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 9
• 210000000988 bone and bone Anatomy 0.000 description 9
• 201000010881 cervical cancer Diseases 0.000 description 9
• 208000024891 symptom Diseases 0.000 description 9
• 201000001342 Fallopian tube cancer Diseases 0.000 description 8
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 8
• 206010019280 Heart failures Diseases 0.000 description 8
• 208000015634 Rectal Neoplasms Diseases 0.000 description 8
• 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 8
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
• 238000013461 design Methods 0.000 description 8
• 208000015181 infectious disease Diseases 0.000 description 8
• 239000013038 irreversible inhibitor Substances 0.000 description 8
• 201000001441 melanoma Diseases 0.000 description 8
• 201000000849 skin cancer Diseases 0.000 description 8
• 206010041823 squamous cell carcinoma Diseases 0.000 description 8
• 230000004083 survival effect Effects 0.000 description 8
• 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 7
• 208000005748 Aggressive Fibromatosis Diseases 0.000 description 7
• 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 7
• 206010061424 Anal cancer Diseases 0.000 description 7
• 201000003076 Angiosarcoma Diseases 0.000 description 7
• 208000007860 Anus Neoplasms Diseases 0.000 description 7
• 206010073360 Appendix cancer Diseases 0.000 description 7
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
• 206010007559 Cardiac failure congestive Diseases 0.000 description 7
• 201000009047 Chordoma Diseases 0.000 description 7
• 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 7
• 206010065859 Congenital fibrosarcoma Diseases 0.000 description 7
• 206010073135 Dedifferentiated liposarcoma Diseases 0.000 description 7
• 206010059352 Desmoid tumour Diseases 0.000 description 7
• 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 7
• 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 7
• 206010061818 Disease progression Diseases 0.000 description 7
• 208000007207 Epithelioid hemangioendothelioma Diseases 0.000 description 7
• 201000005231 Epithelioid sarcoma Diseases 0.000 description 7
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 7
• 208000006168 Ewing Sarcoma Diseases 0.000 description 7
• 208000016803 Extraskeletal Ewing sarcoma Diseases 0.000 description 7
• 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 description 7
• 208000007569 Giant Cell Tumors Diseases 0.000 description 7
• 208000006050 Hemangiopericytoma Diseases 0.000 description 7
• 208000001258 Hemangiosarcoma Diseases 0.000 description 7
• 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 7
• 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 7
• 201000008869 Juxtacortical Osteosarcoma Diseases 0.000 description 7
• 208000007766 Kaposi sarcoma Diseases 0.000 description 7
• 208000008839 Kidney Neoplasms Diseases 0.000 description 7
• 208000032271 Malignant tumor of penis Diseases 0.000 description 7
• 208000000172 Medulloblastoma Diseases 0.000 description 7
• 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 7
• 208000003445 Mouth Neoplasms Diseases 0.000 description 7
• 206010066948 Myxofibrosarcoma Diseases 0.000 description 7
• 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 7
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 7
• 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 7
• 208000013612 Parathyroid disease Diseases 0.000 description 7
• 208000002471 Penile Neoplasms Diseases 0.000 description 7
• 206010034299 Penile cancer Diseases 0.000 description 7
• 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 7
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 7
• 206010038389 Renal cancer Diseases 0.000 description 7
• 206010073139 Round cell liposarcoma Diseases 0.000 description 7
• 208000005718 Stomach Neoplasms Diseases 0.000 description 7
• 208000024313 Testicular Neoplasms Diseases 0.000 description 7
• 206010057644 Testis cancer Diseases 0.000 description 7
• 206010043515 Throat cancer Diseases 0.000 description 7
• 208000024770 Thyroid neoplasm Diseases 0.000 description 7
• 208000002495 Uterine Neoplasms Diseases 0.000 description 7
• 206010047741 Vulval cancer Diseases 0.000 description 7
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 7
• 201000008395 adenosquamous carcinoma Diseases 0.000 description 7
• 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 7
• 208000008524 alveolar soft part sarcoma Diseases 0.000 description 7
• 208000010029 ameloblastoma Diseases 0.000 description 7
• 201000011165 anus cancer Diseases 0.000 description 7
• 208000021780 appendiceal neoplasm Diseases 0.000 description 7
• 201000008791 bone leiomyosarcoma Diseases 0.000 description 7
• 208000035269 cancer or benign tumor Diseases 0.000 description 7
• 201000010882 cellular myxoid liposarcoma Diseases 0.000 description 7
• 201000000292 clear cell sarcoma Diseases 0.000 description 7
• 229940109239 creatinine Drugs 0.000 description 7
• 230000005750 disease progression Effects 0.000 description 7
• 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 7
• 201000004101 esophageal cancer Diseases 0.000 description 7
• 208000032099 esthesioneuroblastoma Diseases 0.000 description 7
• 230000007717 exclusion Effects 0.000 description 7
• 208000020812 extrarenal rhabdoid tumor Diseases 0.000 description 7
• 208000024519 eye neoplasm Diseases 0.000 description 7
• 230000003328 fibroblastic effect Effects 0.000 description 7
• 206010017758 gastric cancer Diseases 0.000 description 7
• 201000010982 kidney cancer Diseases 0.000 description 7
• 208000003849 large cell carcinoma Diseases 0.000 description 7
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 7
• 201000008834 liposarcoma of bone Diseases 0.000 description 7
• 201000007270 liver cancer Diseases 0.000 description 7
• 208000014018 liver neoplasm Diseases 0.000 description 7
• 206010061526 malignant mesenchymoma Diseases 0.000 description 7
• 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 7
• 230000000873 masking effect Effects 0.000 description 7
• 208000029974 neurofibrosarcoma Diseases 0.000 description 7
• 229910052757 nitrogen Inorganic materials 0.000 description 7
• 201000008106 ocular cancer Diseases 0.000 description 7
• 208000022560 parathyroid gland disease Diseases 0.000 description 7
• 201000003434 periosteal osteogenic sarcoma Diseases 0.000 description 7
• 208000010916 pituitary tumor Diseases 0.000 description 7
• 201000009463 pleomorphic rhabdomyosarcoma Diseases 0.000 description 7
• 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 7
• 206010038038 rectal cancer Diseases 0.000 description 7
• 201000001275 rectum cancer Diseases 0.000 description 7
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 7
• 201000008864 small cell osteogenic sarcoma Diseases 0.000 description 7
• 208000014653 solitary fibrous tumor Diseases 0.000 description 7
• 201000011549 stomach cancer Diseases 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 206010042863 synovial sarcoma Diseases 0.000 description 7
• 201000011080 telangiectatic osteogenic sarcoma Diseases 0.000 description 7
• 201000003120 testicular cancer Diseases 0.000 description 7
• 201000002510 thyroid cancer Diseases 0.000 description 7
• 206010044412 transitional cell carcinoma Diseases 0.000 description 7
• 208000010576 undifferentiated carcinoma Diseases 0.000 description 7
• 210000002700 urine Anatomy 0.000 description 7
• 206010046766 uterine cancer Diseases 0.000 description 7
• 206010046885 vaginal cancer Diseases 0.000 description 7
• 208000013139 vaginal neoplasm Diseases 0.000 description 7
• 201000005102 vulva cancer Diseases 0.000 description 7
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
• 241000282414 Homo sapiens Species 0.000 description 6
• 201000010395 Pleomorphic liposarcoma Diseases 0.000 description 6
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 6
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 6
• 230000001640 apoptogenic effect Effects 0.000 description 6
• 238000001574 biopsy Methods 0.000 description 6
• 210000003169 central nervous system Anatomy 0.000 description 6
• 208000035475 disorder Diseases 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 206010061289 metastatic neoplasm Diseases 0.000 description 6
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• 239000002245 particle Substances 0.000 description 6
• 108090000623 proteins and genes Proteins 0.000 description 6
• 208000032843 Hemorrhage Diseases 0.000 description 5
• 241000725303 Human immunodeficiency virus Species 0.000 description 5
• 206010027457 Metastases to liver Diseases 0.000 description 5
• 108091000080 Phosphotransferase Proteins 0.000 description 5
• 150000001413 amino acids Chemical group 0.000 description 5
• 206010003119 arrhythmia Diseases 0.000 description 5
• 208000034158 bleeding Diseases 0.000 description 5
• 230000000740 bleeding effect Effects 0.000 description 5
• 210000000481 breast Anatomy 0.000 description 5
• 150000001721 carbon Chemical group 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 238000002512 chemotherapy Methods 0.000 description 5
• 238000001839 endoscopy Methods 0.000 description 5
• 230000008595 infiltration Effects 0.000 description 5
• 238000001764 infiltration Methods 0.000 description 5
• 210000004698 lymphocyte Anatomy 0.000 description 5
• 210000002540 macrophage Anatomy 0.000 description 5
• 208000010125 myocardial infarction Diseases 0.000 description 5
• 239000008188 pellet Substances 0.000 description 5
• 102000020233 phosphotransferase Human genes 0.000 description 5
• 235000018102 proteins Nutrition 0.000 description 5
• 102000004169 proteins and genes Human genes 0.000 description 5
• 238000001959 radiotherapy Methods 0.000 description 5
• 238000002271 resection Methods 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 238000009121 systemic therapy Methods 0.000 description 5
• 231100000419 toxicity Toxicity 0.000 description 5
• 230000001988 toxicity Effects 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• 102000001554 Hemoglobins Human genes 0.000 description 4
• 108010054147 Hemoglobins Proteins 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
• 208000007814 Unstable Angina Diseases 0.000 description 4
• 239000000654 additive Substances 0.000 description 4
• 150000003973 alkyl amines Chemical class 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 238000002591 computed tomography Methods 0.000 description 4
• 230000034994 death Effects 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 230000009401 metastasis Effects 0.000 description 4
• 239000001301 oxygen Chemical group 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• 230000002980 postoperative effect Effects 0.000 description 4
• 208000037821 progressive disease Diseases 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 239000011593 sulfur Chemical group 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 208000009458 Carcinoma in Situ Diseases 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
• 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• 206010059282 Metastases to central nervous system Diseases 0.000 description 3
• 102100024028 Progonadoliberin-1 Human genes 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 3
• 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
• 230000000996 additive effect Effects 0.000 description 3
• 150000001336 alkenes Chemical class 0.000 description 3
• 150000001345 alkine derivatives Chemical group 0.000 description 3
• 150000001408 amides Chemical class 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 239000005557 antagonist Substances 0.000 description 3
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
• 229940120638 avastin Drugs 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
• 210000003679 cervix uteri Anatomy 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 239000003433 contraceptive agent Substances 0.000 description 3
• 230000002254 contraceptive effect Effects 0.000 description 3
• 125000002993 cycloalkylene group Chemical group 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 229940000406 drug candidate Drugs 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 125000003709 fluoroalkyl group Chemical group 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 208000019622 heart disease Diseases 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 201000004933 in situ carcinoma Diseases 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 238000002595 magnetic resonance imaging Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
• 125000002950 monocyclic group Chemical group 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000002335 preservative effect Effects 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 125000006239 protecting group Chemical group 0.000 description 3
• 208000020016 psychiatric disease Diseases 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 239000008223 sterile water Substances 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 210000003932 urinary bladder Anatomy 0.000 description 3
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
• OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
• 108010082126 Alanine transaminase Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 206010002388 Angina unstable Diseases 0.000 description 2
• 208000010392 Bone Fractures Diseases 0.000 description 2
• 208000020446 Cardiac disease Diseases 0.000 description 2
• 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 2
• 241000252212 Danio rerio Species 0.000 description 2
• 206010011878 Deafness Diseases 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• 208000009139 Gilbert Disease Diseases 0.000 description 2
• 208000022412 Gilbert syndrome Diseases 0.000 description 2
• 208000005176 Hepatitis C Diseases 0.000 description 2
• 101001010823 Homo sapiens Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 101000669434 Mus musculus Transducin-like enhancer protein 1 Proteins 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 208000018262 Peripheral vascular disease Diseases 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 229910007161 Si(CH3)3 Inorganic materials 0.000 description 2
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
• 206010052428 Wound Diseases 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 230000003187 abdominal effect Effects 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 238000009098 adjuvant therapy Methods 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 125000004450 alkenylene group Chemical group 0.000 description 2
• 239000003098 androgen Substances 0.000 description 2
• 238000011225 antiretroviral therapy Methods 0.000 description 2
• 230000006793 arrhythmia Effects 0.000 description 2
• 125000004104 aryloxy group Chemical group 0.000 description 2
• 125000002393 azetidinyl group Chemical group 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 201000008275 breast carcinoma Diseases 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 208000015114 central nervous system disease Diseases 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 235000008504 concentrate Nutrition 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 208000029078 coronary artery disease Diseases 0.000 description 2
• 239000003246 corticosteroid Substances 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• 238000012325 curative resection Methods 0.000 description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 239000003651 drinking water Substances 0.000 description 2
• 235000020188 drinking water Nutrition 0.000 description 2
• 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• HNJBEVLQSNELDL-UHFFFAOYSA-N gamma-butyrolactam Natural products O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
• 229960005277 gemcitabine Drugs 0.000 description 2
• 210000003714 granulocyte Anatomy 0.000 description 2
• 230000035876 healing Effects 0.000 description 2
• 230000010370 hearing loss Effects 0.000 description 2
• 231100000888 hearing loss Toxicity 0.000 description 2
• 208000016354 hearing loss disease Diseases 0.000 description 2
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
• 208000031169 hemorrhagic disease Diseases 0.000 description 2
• 230000002440 hepatic effect Effects 0.000 description 2
• 208000002672 hepatitis B Diseases 0.000 description 2
• 230000002962 histologic effect Effects 0.000 description 2
• 208000019016 inability to swallow Diseases 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 230000003907 kidney function Effects 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 125000005647 linker group Chemical group 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 230000003908 liver function Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 201000005296 lung carcinoma Diseases 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 238000007726 management method Methods 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 230000009251 neurologic dysfunction Effects 0.000 description 2
• 239000002547 new drug Substances 0.000 description 2
• 125000004433 nitrogen atom Chemical group N* 0.000 description 2
• 230000000683 nonmetastatic effect Effects 0.000 description 2
• 150000007523 nucleic acids Chemical group 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 239000005022 packaging material Substances 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 239000008177 pharmaceutical agent Substances 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000011574 phosphorus Substances 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 125000003367 polycyclic group Chemical group 0.000 description 2
• 238000010837 poor prognosis Methods 0.000 description 2
• 238000009597 pregnancy test Methods 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 201000001514 prostate carcinoma Diseases 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 125000004076 pyridyl group Chemical group 0.000 description 2
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 238000004904 shortening Methods 0.000 description 2
• 229910052710 silicon Inorganic materials 0.000 description 2
• 239000010703 silicon Substances 0.000 description 2
• 208000020352 skin basal cell carcinoma Diseases 0.000 description 2
• 201000010106 skin squamous cell carcinoma Diseases 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 150000007970 thio esters Chemical group 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 238000012384 transportation and delivery Methods 0.000 description 2
• 230000008736 traumatic injury Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
• 229960005080 warfarin Drugs 0.000 description 2
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
• LKLLNYWECKEQIB-UHFFFAOYSA-N 1,3,5-triazinane Chemical compound C1NCNCN1 LKLLNYWECKEQIB-UHFFFAOYSA-N 0.000 description 1
• BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
• VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
• WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
• ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 description 1
• IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
• IVJFXSLMUSQZMC-UHFFFAOYSA-N 1,3-dithiole Chemical compound C1SC=CS1 IVJFXSLMUSQZMC-UHFFFAOYSA-N 0.000 description 1
• QVFHFKPGBODJJB-UHFFFAOYSA-N 1,3-oxathiane Chemical compound C1COCSC1 QVFHFKPGBODJJB-UHFFFAOYSA-N 0.000 description 1
• WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical compound C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 description 1
• OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
• JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 1
• CPRVXMQHLPTWLY-UHFFFAOYSA-N 1,4-oxathiine Chemical compound O1C=CSC=C1 CPRVXMQHLPTWLY-UHFFFAOYSA-N 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
• IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
• RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
• QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
• 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
• 125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
• WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
• SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
• MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 description 1
• 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
• UCZQXJKDCHCTAI-UHFFFAOYSA-N 4h-1,3-dioxine Chemical compound C1OCC=CO1 UCZQXJKDCHCTAI-UHFFFAOYSA-N 0.000 description 1
• 206010060921 Abdominal abscess Diseases 0.000 description 1
• 206010001367 Adrenal insufficiency Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 108091007743 BRCA1/2 Proteins 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 229940122361 Bisphosphonate Drugs 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 108010051219 Cre recombinase Proteins 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
• 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 241001125671 Eretmochelys imbricata Species 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 206010016717 Fistula Diseases 0.000 description 1
• 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
• 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
• 101000984551 Homo sapiens Tyrosine-protein kinase Blk Proteins 0.000 description 1
• 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
• 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 206010020802 Hypertensive crisis Diseases 0.000 description 1
• 208000019025 Hypokalemia Diseases 0.000 description 1
• WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 208000007666 Klatskin Tumor Diseases 0.000 description 1
• 101150036626 LSR gene Proteins 0.000 description 1
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
• 206010025476 Malabsorption Diseases 0.000 description 1
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
• 206010025652 Malignant melanoma in situ Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000007650 Meningeal Carcinomatosis Diseases 0.000 description 1
• 206010027450 Metastases to abdominal cavity Diseases 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 208000008457 Neurologic Manifestations Diseases 0.000 description 1
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 208000005228 Pericardial Effusion Diseases 0.000 description 1
• 208000002151 Pleural effusion Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
• 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 206010040943 Skin Ulcer Diseases 0.000 description 1
• 108010009978 Tec protein-tyrosine kinase Proteins 0.000 description 1
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
• YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 208000018452 Torsade de pointes Diseases 0.000 description 1
• 208000002363 Torsades de Pointes Diseases 0.000 description 1
• 208000032109 Transient ischaemic attack Diseases 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• 102100027053 Tyrosine-protein kinase Blk Human genes 0.000 description 1
• 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
• 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 208000011930 active peptic ulcer disease Diseases 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 230000002730 additional effect Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000011292 agonist therapy Methods 0.000 description 1
• 125000003172 aldehyde group Chemical group 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
• 125000005084 alkoxyalkylaminoalkyl group Chemical group 0.000 description 1
• 125000005055 alkyl alkoxy group Chemical group 0.000 description 1
• 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
• 125000005189 alkyl hydroxy group Chemical group 0.000 description 1
• 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
• 125000004419 alkynylene group Chemical group 0.000 description 1
• 150000001412 amines Chemical group 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 238000009167 androgen deprivation therapy Methods 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 239000002518 antifoaming agent Substances 0.000 description 1
• 229940127088 antihypertensive drug Drugs 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 208000007474 aortic aneurysm Diseases 0.000 description 1
• 206010002895 aortic dissection Diseases 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 125000005362 aryl sulfone group Chemical group 0.000 description 1
• 125000005361 aryl sulfoxide group Chemical group 0.000 description 1
• 125000005110 aryl thio group Chemical group 0.000 description 1
• 125000000732 arylene group Chemical group 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
• HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 210000003445 biliary tract Anatomy 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 150000004663 bisphosphonates Chemical class 0.000 description 1
• 208000015294 blood coagulation disease Diseases 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 230000037180 bone health Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 238000007469 bone scintigraphy Methods 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 208000011825 carcinoma of the ampulla of vater Diseases 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 238000009104 chemotherapy regimen Methods 0.000 description 1
• 238000011976 chest X-ray Methods 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 230000002060 circadian Effects 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 238000012321 colectomy Methods 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 201000004365 colon carcinoma in situ Diseases 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 230000000991 decompressive effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000035487 diastolic blood pressure Effects 0.000 description 1
• 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 125000005883 dithianyl group Chemical group 0.000 description 1
• 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 206010013663 drug dependence Diseases 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 201000011523 endocrine gland cancer Diseases 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 238000009093 first-line therapy Methods 0.000 description 1
• 230000003890 fistula Effects 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 125000003838 furazanyl group Chemical group 0.000 description 1
• 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 208000010710 hepatitis C virus infection Diseases 0.000 description 1
• 125000006588 heterocycloalkylene group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 102000053810 human ERBB4 Human genes 0.000 description 1
• WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
• 229940091173 hydantoin Drugs 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 125000005181 hydroxyalkylaminoalkyl group Chemical group 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
• 239000002117 illicit drug Substances 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 150000002576 ketones Chemical group 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 150000003951 lactams Chemical group 0.000 description 1
• 150000002596 lactones Chemical class 0.000 description 1
• 238000002350 laparotomy Methods 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 208000004731 long QT syndrome Diseases 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 208000037841 lung tumor Diseases 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 230000001095 motoneuron effect Effects 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 230000000955 neuroendocrine Effects 0.000 description 1
• 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
• 208000015015 neurological dysfunction Diseases 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• 229960002653 nilutamide Drugs 0.000 description 1
• 125000006574 non-aromatic ring group Chemical group 0.000 description 1
• 230000000474 nursing effect Effects 0.000 description 1
• FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
• 229960000572 olaparib Drugs 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 229940127234 oral contraceptive Drugs 0.000 description 1
• 239000003539 oral contraceptive agent Substances 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000003551 oxepanyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 230000009996 pancreatic endocrine effect Effects 0.000 description 1
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 239000003961 penetration enhancing agent Substances 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000011129 pharmaceutical packaging material Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical compound O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 208000024896 potassium deficiency disease Diseases 0.000 description 1
• 238000009101 premedication Methods 0.000 description 1
• 239000000955 prescription drug Substances 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 201000001474 proteinuria Diseases 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 230000000541 pulsatile effect Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• HNJBEVLQSNELDL-YZRHJBSPSA-N pyrrolidin-2-one Chemical group O=C1CC[14CH2]N1 HNJBEVLQSNELDL-YZRHJBSPSA-N 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 201000011164 rectum carcinoma in situ Diseases 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 230000000630 rising effect Effects 0.000 description 1
• 231100000279 safety data Toxicity 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 201000008261 skin carcinoma Diseases 0.000 description 1
• 201000006000 skin carcinoma in situ Diseases 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 231100000019 skin ulcer Toxicity 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 238000011301 standard therapy Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 208000011117 substance-related disease Diseases 0.000 description 1
• 229960002317 succinimide Drugs 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 230000003319 supportive effect Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000001360 synchronised effect Effects 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000035488 systolic blood pressure Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
• RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
• CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 125000001583 thiepanyl group Chemical group 0.000 description 1
• 125000002053 thietanyl group Chemical group 0.000 description 1
• 125000005309 thioalkoxy group Chemical group 0.000 description 1
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
• BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
• 210000000779 thoracic wall Anatomy 0.000 description 1
• 230000009424 thromboembolic effect Effects 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 201000010875 transient cerebral ischemia Diseases 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
• 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
• 208000029584 urinary system neoplasm Diseases 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 210000000504 visceral peritoneum Anatomy 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1